LGD-4033
From Infogalactic: the planetary knowledge core
240px | |
Systematic (IUPAC) name | |
---|---|
4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile
|
|
Clinical data | |
Legal status |
|
Routes of administration |
Oral |
Pharmacokinetic data | |
Biological half-life | 24-36 hours [1] |
Identifiers | |
CAS Number | 1165910-22-4 |
ATC code | none |
PubChem | CID: 44137686 |
UNII | 1EJT54415A |
Chemical data | |
Formula | C14H12F6N2O |
Molecular mass | 338.25 g·mol−1 |
|
|
|
LGD-4033 (now known as VK5211)[2] is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis, discovered by Ligand Pharmaceuticals and currently under development by Viking Therapeutics.[3][4]
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ VK5211 on BioCentury
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Viking Signs Broad Licensing Deal With Ligand Pharmaceuticals for Rights to Five Novel Therapeutic Programs
Categories:
- Pages with broken file links
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- Hormonal agents
- Organofluorides
- Selective androgen receptor modulators